S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up

ARS Pharmaceuticals (SPRY) Short Interest Ratio & Short Volume

$4.68
-0.08 (-1.68%)
(As of 11/27/2023 ET)
Compare
Today's Range
$4.66
$4.81
50-Day Range
$2.92
$6.61
52-Week Range
$2.55
$9.65
Volume
377,466 shs
Average Volume
748,802 shs
Market Capitalization
$449.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67

ARS Pharmaceuticals Short Interest Data

Current Short Volume
6,600,000 shares
Previous Short Volume
5,670,000 shares
Change Vs. Previous Month
+16.40%
Dollar Volume Sold Short
$23.56 million
Short Interest Ratio / Days to Cover
5.0
Last Record Date
October 31, 2023
Outstanding Shares
96,000,000 shares
Float Size
40,630,000 shares
Short Percent of Float
16.24%
Today's Trading Volume
377,466 shares
Average Trading Volume
748,802 shares
Today's Volume Vs. Average
50%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling ARS Pharmaceuticals ?

Sign up to receive the latest short interest report for ARS Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

SPRY Short Interest Over Time

SPRY Days to Cover Over Time

SPRY Percentage of Float Shorted Over Time


ARS Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/20236,600,000 shares $23.56 million +16.4%16.2%5 $3.57
10/15/20235,670,000 shares $21.15 million -3.4%14.0%4.6 $3.73
9/30/20235,870,000 shares $22.19 million +1.6%14.5%4.9 $3.78
9/15/20235,780,000 shares $41.96 million +7.6%14.2%5.1 $7.26
8/31/20235,370,000 shares $38.07 million -7.7%10.4%10.2 $7.09
8/15/20235,820,000 shares $40.97 million -4.1%12.2%9.7 $7.04
7/31/20236,070,000 shares $44.61 million -2.7%12.8%3.7 $7.35
7/15/20236,240,000 shares $42.62 million +5.2%13.1%3.8 $6.83
6/30/20235,930,000 shares $39.73 million +9.4%12.5%3.7 $6.70
6/15/20235,420,000 shares $32.79 million +22.4%11.4%3.4 $6.05
5/31/20234,430,000 shares $30.83 million +22.4%9.4%3 $6.96
5/15/20233,620,000 shares $28.27 million No Change7.7%2.7 $7.81













SPRY Short Interest - Frequently Asked Questions

What is ARS Pharmaceuticals' current short interest?

Short interest is the volume of ARS Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 31st, investors have sold 6,600,000 shares of SPRY short. 16.24% of ARS Pharmaceuticals' shares are currently sold short. Learn More on ARS Pharmaceuticals' current short interest.

What is a good short interest ratio for ARS Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SPRY shares currently have a short interest ratio of 5.0. Learn More on ARS Pharmaceuticals's short interest ratio.

Which institutional investors are shorting ARS Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ARS Pharmaceuticals: Group One Trading L.P., Belvedere Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for ARS Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.24% of ARS Pharmaceuticals' floating shares are currently sold short.

Is ARS Pharmaceuticals' short interest increasing or decreasing?

ARS Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 6,600,000 shares, an increase of 16.4% from the previous total of 5,670,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is ARS Pharmaceuticals' float size?

ARS Pharmaceuticals currently has issued a total of 96,000,000 shares. Some of ARS Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ARS Pharmaceuticals currently has a public float of 40,630,000 shares.

How does ARS Pharmaceuticals' short interest compare to its competitors?

16.24% of ARS Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to ARS Pharmaceuticals: RAPT Therapeutics, Inc. (11.60%), Liquidia Co. (4.88%), Phathom Pharmaceuticals, Inc. (16.06%), Pharvaris (0.07%), Bicycle Therapeutics plc (14.55%), Edgewise Therapeutics, Inc. (17.04%), Icosavax, Inc. (5.34%), ORIC Pharmaceuticals, Inc. (24.06%), Wave Life Sciences Ltd. (3.62%), Orchard Therapeutics plc (0.15%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: RTX Co. ($9.07 billion), T-Mobile US, Inc. ($3.71 billion), Charter Communications, Inc. ($3.51 billion), Occidental Petroleum Co. ($2.81 billion), Lululemon Athletica Inc. ($2.35 billion), Tractor Supply ($2.26 billion), Coinbase Global, Inc. ($1.88 billion), Rivian Automotive, Inc. ($1.71 billion), Celsius Holdings, Inc. ($1.67 billion), and Newmont Co. ($1.66 billion). View all of the most shorted stocks.

What does it mean to sell short ARS Pharmaceuticals stock?

Short selling SPRY is an investing strategy that aims to generate trading profit from ARS Pharmaceuticals as its price is falling. SPRY shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against ARS Pharmaceuticals?

A short squeeze for ARS Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SPRY, which in turn drives the price of the stock up even further.

How often is ARS Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SPRY, twice per month. The most recent reporting period available is October, 31 2023.



More Short Interest Resources from MarketBeat

This page (NASDAQ:SPRY) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -